SPRY · ARS Pharmaceuticals, Inc.
$5.94
-1.56% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-6.1
Dividend yield
—
Beta
0.88
Avg volume
2M
Employees
0K
2D change
—
5D change
-4.00%
10D change
-17.71%
30D change
-32.55%
60D change
-36.49%
MTD change
-27.46%
YTD change
-50.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SPRY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-25
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-25 | Leerink Partners | Maintains | Outperform | $25.00 → $24.00 |
| 2026-05-28 | Cantor Fitzgerald | Maintains | Overweight | $12.00 → $30.00 |
| 2025-09-04 | Roth Capital | Initiates | Buy | $0.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 23 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 31.5% below the 50-day MA ($8.28).
- Price vs 200-day MA: Trading 37.7% below the 200-day MA ($9.10).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.20) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($5.67).
SPRY Price Chart
Loading chart for SPRY…
Fundamentals
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.